STUDI PENGGUNAAN FONDAPARINUX PADA PASIEN ATRIAL FIBRILASI (Penelitian dilakukan di ICCU dan Irna Kardiologi & Kedokteran Vaskular RSUD Dr.Soetomo Surabaya)

RISKA GUSTINAWATI, 050911101 (2013) STUDI PENGGUNAAN FONDAPARINUX PADA PASIEN ATRIAL FIBRILASI (Penelitian dilakukan di ICCU dan Irna Kardiologi & Kedokteran Vaskular RSUD Dr.Soetomo Surabaya). Skripsi thesis, UNIVERSITAS AIRLANGGA.

[img]
Preview
Text (ABSTRAK)
gdlhub-gdl-s1-2014-gustinawat-29539-7.abstr-t.pdf

Download (245kB) | Preview
[img] Text (FULLTEXT)
gdlhub-gdl-s1-2014-gustinawat-29539-1.FULLTEXT.pdf
Restricted to Registered users only

Download (1MB) | Request a copy
Official URL: http://lib.unair.ac.id

Abstract

Background - One of the drugs therapy in Atrial Fibrillation (AF) is anticoagulant. Patients with intensive care or in the urgent condition need anticoagulant therapy that have rapid onset of action like UFH, LMWH or Fondaparinux. Fondaparinux has several potentially important advantages than UFH and LMWH : It is synthetic, no viral or other animal contaminants, a relatively long half-life, superior bioavailability, predictable dose effect, and does not have cross-reaction with heparin antibody. Objectives – The aim of the study was to identify the utilizing of Fondaparinux in Atrial Fibrillation patients and Drug Related Problems (DRPs) according to using of this anticoagulant. Methods - The analysis was conducted descriptively by using patients medical record (retrospective) which over the period January 2010 to December 2012 (3 years) Results – From 14 patients who received Fondaparinux, 13 patients (93%) given administration 1 x 2,5 mg and 1 patient (7%) with 1 x 5 mg subcutaneously dose. The duration treatment of Fondaparinux was 2-7 days. No potentially drug interaction that occurred in 14 patients who received Fondaparinux with other drugs. Bleeding as a side effect of Fondaparinux was found in 1 patient who received Fondaparinux in this research. Fondaparinux should be effective as an anticoagulant if the aPTT value showed range 1,5 – 2,5 x from normal value. From 14 patients, only 5 patients whose known their aPTT value. Out of all 5 patients there is only one who meet a demand of target therapy. Conclusion – Drug Utilization of Fondaparinux in Dr. Soetomo General Hospital were according to European Society of Cardiology and American College of Chest Physicians Clinical Practice Guidelines Recommendations Keyword : Drug Utilization Study, Fondaparinux, Atrial Fibrillation

Item Type: Thesis (Skripsi)
Additional Information: KKB KK-2 FF.FK 52/13 Gus s
Uncontrolled Keywords: Drug Utilization
Subjects: R Medicine > RS Pharmacy and materia medica > RS1-441 Pharmacy and materia medica
Divisions: 05. Fakultas Farmasi > Farmasi Klinis
Creators:
CreatorsNIM/NIDN
RISKA GUSTINAWATI, 050911101UNSPECIFIED
Contributors:
ContributionNameNIDN/NIDK/NUP
ContributorDr. Suharjono, MS, Apt, Dr., MS, AptUNSPECIFIED
Depositing User: shiefti dyah alyusi
Date Deposited: 21 Jan 2014 12:00
Last Modified: 12 Aug 2016 04:16
URI: http://repository.unair.ac.id/id/eprint/9775
Sosial Share:

Actions (login required)

View Item View Item